Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120,494,078
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
54,512,097
-
Shares change
-
+3,040,159
-
Total reported value, excl. options
-
$106,299,597
-
Value change
-
+$5,482,917
-
Number of buys
-
34
-
Number of sells
-
-29
-
Price
-
$1.95
Significant Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q2 2025
71 filings reported holding IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2025.
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54,512,097 shares
of 120,494,078 outstanding shares and own 45% of the company stock.
Largest 10 shareholders include Sands Capital Alternatives, LLC (10,950,000 shares), Soleus Capital Management, L.P. (6,325,000 shares), Fairmount Funds Management LLC (6,125,000 shares), PERCEPTIVE ADVISORS LLC (5,432,293 shares), Commodore Capital LP (5,397,488 shares), ADAR1 Capital Management, LLC (5,122,105 shares), VANGUARD GROUP INC (3,224,370 shares), BlackRock, Inc. (2,728,168 shares), Blackstone Inc. (2,638,276 shares), and Nantahala Capital Management, LLC (2,190,000 shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.